Mineralys Therapeutics (MLYS) Interest Expenses (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Interest Expenses of $146.3 million for Q4 2025, up 83.06% sequentially from $79.9 million in Q4 2024, and up 83.06% YoY from $79.9 million in Q4 2024.
Mineralys Therapeutics (MLYS) Interest Expenses (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Interest Expenses for 4 years, with the latest figure at $146.3 million in Q4 2025.
- Quarterly Interest Expenses rose 83.06% year-over-year to $146.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146.3 million (up 83.06% YoY) and the FY2025 annual result came in at $146.3 million, up 83.06% from the prior year.
- Interest Expenses advanced to $146.3 million in Q4 2025 per MLYS's latest filing, from $79.9 million in the prior quarter.
- Over five years, Interest Expenses peaked at $146.3 million in Q4 2025 and troughed at $183000.0 in Q4 2022.
- A 4-year average of $56.8 million and a median of $40.4 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 9226.6% in 2024, then surged 83.06% in 2025.
- Over 4 years, Interest Expenses stood at $183000.0 in 2022, then soared by 368.31% to $857000.0 in 2023, then surged by 9226.6% to $79.9 million in 2024, then soared by 83.06% to $146.3 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $146.3 million, $79.9 million, and $857000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.38 Mn |
| Jun 30, 2026 | 2.38 Mn |
| Dec 31, 2025 | 146.32 Mn |
| Dec 31, 2025 | 146.32 Mn |
| Dec 31, 2024 | 79.93 Mn |
| Dec 31, 2024 | 79.93 Mn |
| Dec 31, 2023 | 857,000.00 |
| Dec 31, 2023 | 857,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Dec 31, 2022 | 183,000.00 |